# AML MRD ‚Äî Flow Cytometry Resources

> Ressources s√©lectionn√©es pour analyser la **maladie r√©siduelle mesurable (MRD)** dans les **leuc√©mies aigu√´s my√©lo√Ødes (LAM)** par **cytom√©trie en flux** (CMF) : algorithmes et jeu de donn√©es

[![PRs Welcome](https://img.shields.io/badge/PRs-welcome-brightgreen.svg)](#comment-contribuer)
[![MIT License](https://img.shields.io/badge/License-MIT-yellow.svg)](./LICENSE)


## Table des mati√®res
- [Qualit√© & pr√©traitement](#qualit√©--pr√©traitement)
- [Gating (manuel & automatique)](#gating-manuel--automatique)
- [R√©duction de dimension et visualisation](#r√©duction-de-dimension-et-visualisation)
- [Outils & pipelines](#outils--pipelines)
- [Jeux de donn√©es publics](#jeux-de-donn√©es-publics)
- [Tutoriels & notebooks](#tutoriels--notebooks)
- [Articles cl√©s & revues](#articles-cl√©s--revues)
- [Comment contribuer](#comment-contribuer)
- [Licence & citation](#licence--citation)

---

## Qualit√© & pr√©traitement
### Normalisation
- **CytoNorm 2.0** ‚Äî *A Flexible Normalization Framework for Cytometry Data without Requiring Dedicated Controls*.  
  *Cytometry Part A, Quintelier K.L.A., Willemsen M., Bosteels V., Aerts J.G.J.V., Saeys Y., Van Gassen S., (s.d.)*.  
  [DOI:10.1002/cyto.a.24910](https://doi.org/10.1002/cyto.a.24910)

## Gating (manuel & automatique)
- *(ex. strat√©gies AML MRD, openCyto, r√®gles, mod√®les appris)*

## R√©duction de dimension et visualisation
### Transport optimal
- **Transport optimal** ‚Äî *Low Dimensional Representation of Multi‚ÄêPatient Flow Cytometry Datasets Using Optimal Transport for Measurable Residual Disease Detection in Leukemia*.  
  *Cytometry Part A, Gachon E., Bigot J., Cazelles E., et al., 2025*.  
  [DOI:10.1002/cyto.a.24918](https://doi.org/10.1002/cyto.a.24918)

- **Transport optimal** ‚Äî *An Optimal Transport-Based Low-Dimensional Visualization Framework for High-Parameter Flow Cytometry*.  
  *Pr√©publication (Bioinformatics), Shemonti A., Gmyrek G.B., Quintelier K.L.A., et al., 24 ao√ªt 2025*.  
  [DOI:10.1101/2025.08.19.670604](https://doi.org/10.1101/2025.08.19.670604)

### FlowSOM
- **FlowSOM (Self-Organizing Maps)** ‚Äî *FlowSOM: Using Self-Organizing Maps for Visualization and Interpretation of Cytometry Data*.  
  *Cytometry Part A, Van Gassen S., Callebaut B., Van Helden M.J., et al., 2015*.  
  [DOI:10.1002/cyto.a.22625](https://doi.org/10.1002/cyto.a.22625)
- **FlowSOM (R)** ‚Äî *An R-Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data*.  
  *Cytometry Part A, Lacombe F., Lechevalier N., Vial J.P., B√©n√© M.C., 2019*.  
  [DOI:10.1002/cyto.a.23897](https://doi.org/10.1002/cyto.a.23897)

### Gaussian Mixture Models (GMM)
- **Computational MRD validation (HOVON-SAKK-132)** ‚Äî *Computational measurable residual disease assessment in acute myeloid leukemia: A retrospective validation in the HOVON-SAKK-132 trial*.  
  *Leukemia, Mocking T.R., Haaksma L.H., Reuvekamp T., Kelder A., Scholten W.J., Ngai L.L., Breems D.A., Fischer T., Gjertsen B.T., Gri≈°keviƒçius L., Juliusson G., Maertens J.A., Manz M.G., Pabst T., Passweg J.R., Porkka K., Valk P.J.M., Gradowska P., L√∂wenberg B., Bachas C., 2025*.  
  [DOI:10.1038/s41375-025-02747-8](https://doi.org/10.1038/s41375-025-02747-8)
  üí° *Une √©valuation r√©trospective de l'algorithme GMMc de Mocking et al. sur la cohorte HOVON-SAKK-132, qui montre une meilleure pr√©diction de la rechute que la m√©thode manuelle. √Ä noter : seuil "custom" dont la fixation entra√Æne peut-√™tre un risque d‚Äôoverfitting.*


## Outils & pipelines

- **MAGIC-DR** ‚Äî *An Interpretable Machine-Learning Guided Approach for Acute Myeloid Leukemia Measurable Residual Disease Analysis*.  
  *Cytometry Part B: Clinical Cytometry, Shopsowitz K., Lofroth J., Chan G., et al., 2024*.  
  [DOI:10.1002/cyto.b.22168](https://doi.org/10.1002/cyto.b.22168)
  
- **Mixture Models for MRD** ‚Äî *Computational Assessment of Measurable Residual Disease in Acute Myeloid Leukemia Using Mixture Models*.  
  *Communications Medicine, Mocking T.R., Kelder A., Reuvekamp T., et al., 2024*.  
  [DOI:10.1038/s43856-024-00700-x](https://doi.org/10.1038/s43856-024-00700-x)

## Jeux de donn√©es publics
- **FlowCAP / DREAM AML dataset (FR-FCM-ZZYA)** ‚Äî Jeu de donn√©es de cytom√©trie en flux (FCS) utilis√© dans les challenges **FlowCAP** et **DREAM** pour l‚Äô√©valuation comparative des m√©thodes d‚Äôanalyse automatis√©e.  
  Contient plusieurs centaines d‚Äô√©chantillons (AML vs non-AML, diagnostics de leuc√©mie aigu√´ my√©lo√Øde et t√©moins), avec panels multicolores standards.  
  Sert de **benchmark de r√©f√©rence** pour tester et comparer les algorithmes de gating, clustering et classification appliqu√©s √† la MRD en LAM.  
  *R√©f√©rence* : Aghaeepour N., Finak G., FlowCAP Consortium, DREAM Consortium, et al. *Critical Assessment of Automated Flow Cytometry Data Analysis Techniques*. **Nature Methods**, 10(3):228-38, 2013.  
  [DOI:10.1038/nmeth.2365](https://doi.org/10.1038/nmeth.2365) ¬∑ [FlowRepository FR-FCM-ZZYA](http://flowrepository.org/id/FR-FCM-ZZYA)

## Tutoriels & notebooks
- *(guides pas-√†-pas, cours, ateliers)*

## Articles cl√©s & revues

- **Review ML for MRD** ‚Äî *Applications of Machine Learning for Immunophenotypic Measurable Residual Disease Assessment in Acute Myeloid Leukemia*.  
  *HemaSphere, Mocking T.R., van de Loosdrecht A.A., Cloos J., Bachas C., 2025*.  
  [DOI:10.1002/hem3.70138](https://doi.org/10.1002/hem3.70138)


---

## Comment contribuer
Les contributions ne sont pas encore possible, mais √ßa va venir...

## Licence & citation
- Contenu : [MIT License](./LICENSE).
- Pour citer ce d√©p√¥t, utilisez le fichier [`CITATION.cff`](./CITATION.cff).
